Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates

Company Performance - Amicus Therapeutics reported quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share, and down from $0.06 per share a year ago, representing an earnings surprise of -50.00% [1] - The company posted revenues of $154.69 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.87%, compared to year-ago revenues of $126.67 million [2] - Over the last four quarters, Amicus Therapeutics has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Stock Performance - Amicus Therapeutics shares have lost about 34.9% since the beginning of the year, while the S&P 500 has gained 8.2% [3] - The current status of estimate revisions translates into a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.11 on revenues of $164.66 million, and $0.32 on revenues of $621.22 million for the current fiscal year [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8]